<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>eGenesis — Prospect Detail</title>
  <link rel="stylesheet" href="styles.css">
</head>
<body>
<header class="site-header"><h1>Prospect Detail</h1></header>
<div class="container">
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
  <div class="detail-header">
    <span class="badge health" style="font-size:.8rem;">Biotech / Transplant</span>
    <h1>132. eGenesis</h1>
    <p class="meta">CRISPR-Engineered Pig Organs for Human Transplant</p>
  </div>
  <div class="section"><h3>1. Startup Name</h3><p><strong>eGenesis</strong></p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Tell me more about this company's origin story...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>2. Founder Contact</h3><p><strong>George Church & Luhan Yang</strong></p><p>Wyss Institute / Harvard Medical School</p><p>Dr. Church is a legendary geneticist and pioneer of CRISPR technology; Dr. Yang led groundbreaking xenotransplantation research at Harvard</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Research the founder's background and credentials...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>3. Product Overview</h3><p>eGenesis uses CRISPR gene editing to develop pig organs suitable for human transplantation (xenotransplantation). By making dozens of genetic modifications to pig cells, eGenesis removes pig viruses and modifies immune-related genes to prevent rejection. The company has achieved historic milestones including the first successful pig kidney transplants into living human patients, addressing the critical organ shortage crisis affecting 100,000+ patients on transplant waiting lists.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What competitors does this product face?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>4. Funding Stage</h3><p><strong>Series D — $191M</strong> — Well-funded to advance clinical trials and scale production of gene-edited pig organs.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What's the typical next funding milestone?">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section"><h3>5. How I Found the Company</h3><p>Discovered through Wyss Institute portfolio research and coverage of historic xenotransplantation breakthroughs.</p>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Find more recent news about this company...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="strengths-weaknesses">
    <div class="section"><h3>Strengths</h3><ul><li><strong>Historic clinical success:</strong> First successful pig-to-human kidney transplants represent a major scientific breakthrough.</li><li><strong>World-class founders:</strong> George Church is a legendary figure in genetics; deep Harvard/Wyss expertise.</li><li><strong>Massive market need:</strong> Over 100,000 patients on organ transplant waiting lists in the US alone.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Validate these strengths with market data...">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
    <div class="section"><h3>Weaknesses</h3><ul><li><strong>Regulatory complexity:</strong> FDA approval pathway for xenotransplantation is uncharted territory.</li><li><strong>Long-term unknowns:</strong> Multi-year patient outcomes still being studied.</li><li><strong>Ethical considerations:</strong> Animal welfare and religious concerns may limit some patient populations.</li></ul>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="What other risks should I consider?">
        <button>Ask AI</button>
      </div>
    </div>
    </div>
  </div>
  <div class="section"><h3>7. Five Questions for the Team</h3><ol class="questions-list"><li>What is the current status of FDA regulatory discussions for xenotransplantation?</li><li>How long have the longest-surviving kidney transplant patients maintained organ function?</li><li>What is your timeline and cost projection for scaling pig organ production?</li><li>Are you developing other organs beyond kidneys (heart, liver)?</li><li>How do you address immunosuppression requirements compared to human organ transplants?</li></ol>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Generate additional due diligence questions...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <div class="section email-draft">
    <h3>8. Draft Outreach Email</h3>
    <div class="email-box">
      <p><strong>Subject:</strong> Harvard Undergraduate Capital Partners — Inspired by eGenesis's Historic Breakthroughs</p>
      <p>Dear eGenesis Team,</p>
      <p>I'm reaching out from <strong>Harvard Undergraduate Capital Partners (HUCP)</strong>, a student-run investment group at Harvard focused on early-stage ventures led by Harvard-affiliated founders.</p>
      <p>We've been following eGenesis's groundbreaking work in xenotransplantation with tremendous interest. The successful pig-to-human kidney transplants represent a truly historic achievement born from Dr. Church and Dr. Yang's pioneering research at the Wyss Institute and Harvard Medical School. The potential to address the organ shortage crisis affecting over 100,000 patients is remarkable.</p>
      <p>We understand eGenesis is well-funded through Series D, but we would be honored to learn more about your journey from Harvard labs to clinical breakthroughs. Would anyone on the team be open to a brief conversation with students from your Harvard community?</p>
      <p>Thank you for your consideration.</p>
      <p>Best,<br>[Your Name]<br>Harvard Undergraduate Capital Partners</p>
    </div>
    <div class="ai-dialogue">
      <div class="ai-dialogue-label">Ask AI to verify or expand</div>
      <div class="ai-dialogue-input">
        <input type="text" placeholder="Personalize this email with more specific details...">
        <button>Ask AI</button>
      </div>
    </div>
  </div>
  <a href="index.html" class="back-link">&larr; Back to All Prospects</a>
</div>
<script src="script.js?v=4"></script>
</body>
</html>
